Organigram Global Inc. Secures Shareholder Approval for Sanity Group Acquisition and Private Placement with BAT
Organigram Global Inc. (NASDAQ: OGI, TSX: OGI) announced on March 30, 2026 that its shareholders, convened for the annual general and special meeting, voted overwhelmingly to approve the resolution necessary to consummate the previously disclosed acquisition of Sanity Group GmbH. The decision also sanctioned the related private placement financing with BT DE Investments Inc., a wholly‑owned subsidiary of British American Tobacco (BAT).
Transaction Details
| Item | Description |
|---|---|
| Acquisition Target | Sanity Group GmbH, a German‑based medical‑marijuana producer |
| Share Structure | Indirect acquisition of all outstanding shares of Sanity Group not already owned by Organigram |
| Private Placement | Issuance of up to 96,287,602 common shares to the shareholders of Sanity Group in exchange for their equity |
| Financing Partner | BT DE Investments Inc., affiliated with BAT |
| Resolution Type | Ordinary resolution authorizing the transaction and related share issuance |
The shareholders approved the ordinary resolution that authorizes:
- The indirect purchase of Sanity Group’s remaining shares, thereby consolidating full ownership under Organigram.
- The issuance of up to 96,287,602 new common shares to Sanity Group shareholders as part of the private placement, thereby providing liquidity and aligning interests.
Strategic Rationale
Organigram’s board positions this deal as a pivotal expansion of its medical‑marijuana portfolio in Canada and Europe. By acquiring Sanity Group, the company gains access to established cultivation sites, regulatory approvals, and a diversified patient base. The private placement with BAT’s subsidiary injects capital that can be deployed toward scaling operations, research and development, and potential entry into new markets.
Market Impact
At the close of March 26, 2026, Organigram’s stock traded at CAD 1.81, a modest decline from its 52‑week high of CAD 3.09 (December 17, 2025) but well above its 52‑week low of CAD 1.22 (April 8, 2025). With a market capitalization of approximately CAD 246 million and a price‑to‑earnings ratio of 13.74, the company remains undervalued relative to peers in the health‑care pharmaceutical sector.
The shareholder approval of the acquisition and financing is expected to enhance Organigram’s competitive position, broaden its product offerings, and provide a stronger foundation for future growth initiatives.
This article summarizes the latest corporate action for Organigram Global Inc. based on the company’s own disclosure and publicly available financial data.
